Mesenchymal stem cells and vascular regeneration

Gu, Wenduo; Hong, Xuechong; Potter, Claire M.F.; Qu, Aijuan; Xu, Qingbo

doi:10.1111/micc.12324

Cited by 81 publications

(59 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, it has already been described that MSCs could play a crucial role in the modulation of angiogenesis in several models like hindlimb ischemia ( 53 , 54 ). They were able to produce cytokines and growth factors which could protect endothelial cells from apoptosis and to promote angiogenesis ( 55 ). Therefore, several authors investigated the possible paracrine therapeutic role of MSCs in the pathogenesis of SSc.…”

Section: Rational Of Msc-based Therapy Of Sscmentioning

confidence: 99%

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges

Peltzer¹,

Aletti

Frescaline

et al. 2018

Front. Immunol.

View full text Add to dashboard Cite

Systemic Sclerosis (SSc) is a rare chronic disease, related to autoimmune connective tissue diseases such as Systemic Lupus Erythematosus and Sjögren's Syndrome. Although its clinical heterogeneity, main features of the disease are: extensive tissue fibrosis with increase matrix deposition in skin and internal organ, microvascular alterations and activation of the immune system with autoantibodies against various cellular antigens. In the diffuse cutaneous scleroderma subtype, the disease is rapidly progressive with a poor prognosis, leading to failure of almost any internal organ, especially lung which is the leading cause of death. Primary trigger is unknown but may involve an immune process against mesenchymal cells in a genetically receptive host. Pathophysiology reveals a pivotal role of fibrosis and inflammation alterations implicating different cell subtypes, cytokines and growth factors, autoantibodies and reactive oxygen species. Despite improvement, the overall survival of SSc patients is still lower than that of other inflammatory diseases. Recommended drugs are agents capable of modulating fibrotic and inflammatory pathways. Cellular therapy has recently emerged as a credible option. Besides autologous hematopoietic stem cell transplantation which demonstrated remarkable improvement, mesenchymal stromal cells (MSCs) represent promising therapeutic candidates. Indeed, these cells possess anti-inflammatory, antiproliferative, antifibrotic, and immunomodulary properties especially by secreting a large panel of bioactive molecules, addressing the most important key points of the SSc. In addition, these cells are very sensitive to their environment and are able to modulate their activity according to the pathophysiological context in which they are located. Autologous or allogeneic MSCs from various sources have been tested in many trials in different auto-immune diseases such as multiple sclerosis, Crohn's disease or systemic lupus erythematosus. They are characterized by a broad availability and no or low acute toxicity. However, few randomized prospective clinical trials were published and their production under ATMP regulatory procedures is complex and time-consuming. Many aspects have still to be addressed to ascertain their potential as well as the potential of their derived products in the management of SSc, probably in association with other therapies.

show abstract

Section: Rational Of Msc-based Therapy Of Sscmentioning

confidence: 99%

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges

Peltzer¹,

Aletti

Frescaline

et al. 2018

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…28 Many investigations have established that human bone marrow mesenchymal stem cells (hBMSCs) can repair vascular injuries. 29,30 hBMSCs have been shown to home preferentially to areas of injury in response to signals of cellular damage, known as homing signals. 31 The hBMSCs home to injured sites and secrete growth factors, which may play an important role in tissue regeneration and repair.…”

Section: Introductionmentioning

confidence: 99%

<p>Multifunctional PLGA-based nanoparticles as a controlled release drug delivery system for antioxidant and anticoagulant therapy</p>

Lee¹,

Zan²,

Chen³

et al. 2019

IJN

View full text Add to dashboard Cite

Background Ischemia/reperfusion (I/R) injury causes the generation of many ROS such as H 2 O 2 and leads to vascular thrombosis, which causes tissue damage. Purpose In this investigation, poly (lactideco-glycolide) (PLGA)-based nanoparticles are used for their anticoagulant and antioxidant properties in vascular therapy. Methods Both heparin and glutathione are entrapped on PLGA-stearylamine nanoparticles by layer-by-layer interactions. Results The drug release rate is successfully controlled with only 10.3% of the heparin released after 96 hours. An H 2 O 2 -responsive platform is also developed by combining silk fibroin and horse peroxidase to detect H 2 O 2 in this drug delivery system. Besides, hyaluronic acid was decorated on the surface of nanoparticles to target the human bone marrow mesenchymal stem cells (hBMSCs) for cell therapy. The results of an in vitro study indicate that the nanoparticles could be taken up by hBMSCs within 2 hours and exocytosis occurred 6 hours after cellular uptake. Conclusion We propose that the multifunctional nanoparticles that are formed herein can be effectively delivered to the site of an I/R injury via the hBMSC homing effect. The proposed approach can potentially be used to treat vascular diseases, providing a platform for hBMSCs for the controlled delivery of a wide range of drugs.

show abstract

“…Accumulating evidence shows that MSCs primarily reside within the perivascular zone of both the adventitial layer of large vessels and the pericyte niche of microvessels in multiple organs (2,3,4). Many studies proposed that MSCs participate in maintaining the tissue homeostasis and contributing to the tissue regeneration in response to injury.…”

Section: Introductionmentioning

confidence: 99%

Plasticity of vascular resident mesenchymal stromal cells during vascular remodeling

Hong

2019

Vascular Biology

Self Cite

View full text Add to dashboard Cite

Vascular remodeling is a complex and dynamic pathological process engaging many different cell types that reside within the vasculature. Mesenchymal stromal/stem cells (MSCs) refer to a heterogeneous cell population with the plasticity to differentiate toward multiple mesodermal lineages. Various types of MSC have been identified within the vascular wall that actively contribute to the vascular remodeling process such as atherosclerosis. With the advances of genetic mouse models, recent findings demonstrated the crucial roles of MSCs in the progression of vascular diseases. This review aims to provide an overview on the current knowledge of the characteristics and behavior of vascular resident MSCs under quiescence and remodeling conditions, which may lead to the development of novel therapeutic approaches for cardiovascular diseases.

show abstract

Mesenchymal stem cells and vascular regeneration

Cited by 81 publications

References 185 publications

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges

<p>Multifunctional PLGA-based nanoparticles as a controlled release drug delivery system for antioxidant and anticoagulant therapy</p>

Plasticity of vascular resident mesenchymal stromal cells during vascular remodeling

Contact Info

Product

Resources

About